Press Releases May 1, 2026 03:10 AM

Director/PDMR Shareholding

Magnum Ice Cream CFO Acquires 20,000 Shares in Latest Transaction

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
MICC

The Magnum Ice Cream Company N.V. announced a transaction where the Chief Financial Officer, Abhijit Bhattacharya, acquired 20,000 ordinary shares on the Amsterdam Stock Exchange. This insider purchase reflects confidence in the company but does not indicate major strategic changes.

Director/PDMR Shareholding
MICC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Acquisition of 20,000 ordinary shares by CFO Abhijit Bhattacharya at €12.48 per share.
  • Shares traded on the Amsterdam Stock Exchange (Euronext) with ISIN NL0015002MS2.
  • The company is a global leader in the ice cream business with a broad portfolio including Magnum, Ben & Jerry's, Cornetto, and Heartbrand, operating in 80 markets worldwide.

The Magnum Ice Cream Company N.V.

(TMICC or the Company)

NOTIFICATION OF A TRANSACTION OF A PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR)

The Company notifies the following acquisition of ordinary shares of €3.50 each (Shares) of a PDMR.

This announcement is made in accordance with the requirements of the EU and UK version of the Market Abuse Regulation 596/2014. 

 1

 Details of the person discharging managerial responsibilities/person closely associated

  a)

 Name of natural personAbhijit Bhattacharya 2

 Reason for the notification

  a)

 Position/status

 

 Chief Financial Officer b)

 Initial notification/Amendment

 

 Initial notification 3

 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

  a)

 Name

 

 The Magnum Ice Cream Company N.V. b)

 Legal Entity Identifier code

 

 25490052LLF3XH6G9847 4

 Details of the transaction(s) summary table  Date of TransactionDescription of InstrumentIdentification CodePlace of TransactionCurrency  30-APR-2026Ordinary shares of €3.50 eachISIN: NL0015002MS2Amsterdam Stock Exchange - XAMSEUR  Nature of Transaction 

 

PriceVolumeTotal  Acquisition12.48

20,000

249,600   Aggregated12.4820,000249,600   




Enquiries Media Relations
media.relations-tmicc@magnumicecream.com

Investor Relations
investor.relations-tmicc@magnumicecream.com

About The Magnum Ice Cream Company

The Magnum Ice Cream Company N.V. (EURONEXT: MICC/ NYSE: MICC/ LSE: MICC) is the world's leading ice cream business. Home to four of the world's five largest ice cream brands: Magnum, Ben & Jerry's, Cornetto and the Heartbrand, our portfolio delights consumers in 80 markets around the world. Headquartered in Amsterdam, The Netherlands, we have a global team of 18,000 employees, a network of 32 factories, 13 R&D centres, and a fleet of three million freezer cabinets. For more information, visit www.corporate.magnumicecream.com. TMICC's legal entity identifier is 25490052LLF3XH6G9847.


Risks

  • Share acquisitions do not guarantee improved company financial performance or stock growth, market and operational risks remain.
  • Global ice cream market influenced by consumer tastes, economic fluctuations, and supply chain disruptions impacting performance.
  • Regulatory changes in multiple countries can affect international operations and profitability.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026